Human plasma is the critical component of numerous therapeutic products used in the treatment of life-threatening diseases, including bleeding disorders, immune system disorders and several other severe pathologies. In recent years, the global use of and demand for plasma for fractionation has grown and this trend is expected to continue.
European patients are highly dependent on USA collected plasma, which puts Europe at risk in case of any sudden supply interruptions. It is therefore important that plasma collection by blood services is intensified within Europe while protecting donors’ rights.
This symposium will discuss the facts and scientific evidence surrounding the collection of plasma for fractionation and the elaboration of donor eligibility criteria to ensure donor protection. Evidence-based data will be used to revise the text of the next edition of the ‘Guide to the preparation, use and quality assurance of blood components’ (20th Edition), published by the EDQM/Council of Europe.
This symposium will:
- Discuss the obstacles to strategic independence of plasma for fractionation in Europe;
- Discuss donor safety, donor selection and donor management;
- Provide an update on national and international regulations and current developments.
The symposium will be a unique opportunity to meet and interact with experts who have practical experience and knowledge in the field of plasma supply management and in the elaboration of strategies to increase the availability of plasma for fractionation.
The presentations will be followed by several Q&A sessions.
Who should attend?
This symposium should be of interest to health care professionals working in the field of blood transfusion